Literature DB >> 11893734

Biochemical characterization of the core structure of alpha-synuclein filaments.

Hirotomo Miake1, Hidehiro Mizusawa, Takeshi Iwatsubo, Masato Hasegawa.   

Abstract

Intracellular filamentous aggregates comprised of alpha-synuclein such as Lewy bodies and glial cytoplasmic inclusions are the defining hallmarks of a subset of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. We have analyzed biochemical and structural properties of alpha-synuclein filaments assembled in vitro or extracted from brains of patients with multiple system atrophy and found that both types of filaments are insoluble to detergents and partially resistant to proteinase K digestion. Immunoelectron microscopy and immunoblot analysis showed that both amino and carboxyl termini of alpha-synuclein in in vitro assembled filaments were degraded by proteinase K treatment, whereas the central portion of alpha-synuclein is resistant to proteinase K and retains filamentous structures. Protein sequencing and mass spectrometric analyses of the proteinase K-resistant, minimal fragment of 7 kDa revealed that amino acid residues 31-109 of alpha-synuclein constitute the core unit of the filaments. These observations suggest that the central half of the alpha-synuclein polypeptide, containing five tandem repeats as well as a part of the carboxyl-terminal acidic region, forms the core structure of alpha-synuclein filaments, which is coated by the amino- and carboxyl-terminal portions at the periphery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893734     DOI: 10.1074/jbc.M110551200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  93 in total

1.  Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations.

Authors:  L M Patrias; A C Klaver; M P Coffey; D A Loeffler
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

2.  Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.

Authors:  Sarah L DeVos; Bianca T Corjuc; Caitlin Commins; Simon Dujardin; Riley N Bannon; Diana Corjuc; Benjamin D Moore; Rachel E Bennett; Mehdi Jorfi; Jose A Gonzales; Patrick M Dooley; Allyson D Roe; Rose Pitstick; Daniel Irimia; Matthew P Frosch; George A Carlson; Bradley T Hyman
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

3.  Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse.

Authors:  Isin Unal-Cevik; Yasemin Gursoy-Ozdemir; Muge Yemisci; Sevda Lule; Gunfer Gurer; Alp Can; Veronica Müller; Philip J Kahle; Turgay Dalkara
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-29       Impact factor: 6.200

4.  Interactive sequences in the molecular chaperone, human alphaB crystallin modulate the fibrillation of amyloidogenic proteins.

Authors:  Joy G Ghosh; Scott A Houck; John I Clark
Journal:  Int J Biochem Cell Biol       Date:  2007-11-13       Impact factor: 5.085

5.  A general strategy for the bacterial expression of amyloidogenic peptides using BCL-XL-1/2 fusions.

Authors:  Isaac T Yonemoto; Malcolm R Wood; William E Balch; Jeffery W Kelly
Journal:  Protein Sci       Date:  2009-09       Impact factor: 6.725

6.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

Review 7.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

8.  E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.

Authors:  Ignacio Íñigo-Marco; Miguel Valencia; Laura Larrea; Ricardo Bugallo; Mikel Martínez-Goikoetxea; Iker Zuriguel; Montserrat Arrasate
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

9.  Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.

Authors:  Michael Bidinosti; Derya R Shimshek; Brit Mollenhauer; David Marcellin; Tatjana Schweizer; Gregor P Lotz; Michael G Schlossmacher; Andreas Weiss
Journal:  J Biol Chem       Date:  2012-07-27       Impact factor: 5.157

Review 10.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.